![](https://www.abta.org/wp-content/uploads/2023/03/ABTA-Lucien-Rubinstein-300x300.png)
David Hou Awarded 2022 ABTA Lucien Rubinstein Award for ‘B Cell Vaccine Promotes Anti-Glioma Immunity Through Modulating CD8+ T Cells’
David Hou is awarded for his research on leveraging a B cell vaccine to improve immunotherapy treatment for GBM.
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
David Hou is awarded for his research on leveraging a B cell vaccine to improve immunotherapy treatment for GBM.
**Sponsored Content**
For adult patients with recurrent GBM, a new clinical trial may offer access to emerging solutions and novel therapies unavailable elsewhere.
On November 17, 2022, results from a phase 3 trial of DCVax-L, an immunotherapy for glioblastoma patients, were published in the Journal of the American Medical Association (JAMA) Oncology.
Meet two researchers on opposite ends of the globe dedicated to transforming the future of brain tumor treatments.
**Sponsored Content**
See how a cutting-edge imaging solution by Medexus Pharma is revolutionizing treatment outcomes for GBM patients.
Dr. Duane Mitchell, MD, PhD, Univ. of Florida, shares four highlights in recent GBM research and what he’s hopeful for in the future.
Always free for patients & caregivers
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631